Cargando…

TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma

BACKGROUND & AIMS: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is prevalent worldwide. Despite its limitations, serum alpha-fetoprotein (AFP) remains the most widely-used biomarker for the diagnosis of HCC. This study aimed to assess whether measurement of peripheral plasma Di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Liping, Wang, Yueguo, Wang, Delin, Han, Gang, Fu, Shouzhong, Wang, Jianxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597119/ https://www.ncbi.nlm.nih.gov/pubmed/28902891 http://dx.doi.org/10.1371/journal.pone.0183880

Ejemplares similares

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

AFP
Publicado: (2009)

Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma
por: HOU, SI-CONG, et al.
Publicado: (2013)

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
por: Wang, Ting, et al.
Publicado: (2020)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

Status of AFP
por: Erland, Paula Agnieszka
Publicado: (2019)

The AFP Project
por: Staszewski, R.
Publicado: (2011)

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis
por: Wang, Xueying, et al.
Publicado: (2020)

Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level
por: Force, Madison, et al.
Publicado: (2022)

Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma
por: Wang, Xueping, et al.
Publicado: (2019)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels
por: Zhang, Xi, et al.
Publicado: (2020)

Identification of Plasma hsa_circ_0005397 and Combined With Serum AFP, AFP-L3 as Potential Biomarkers for Hepatocellular Carcinoma
por: Liu, Ruoyu, et al.
Publicado: (2021)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Establishment and validation of nomogram model for the diagnosis of AFP-negative hepatocellular carcinoma
por: Liu, Long, et al.
Publicado: (2023)

DCS and TDAQ for AFP
por: Banas, Elzbieta, et al.
Publicado: (2017)

AFP Project in ATLAS
por: Tasevsky, M
Publicado: (2017)

First AFP results
por: Staszewski, Rafal
Publicado: (2017)

Overview of AFP performance
por: Liu, Jesse Kar Kee
Publicado: (2021)

The ATLAS AFP Spectrometer
por: Newman, Paul Richard
Publicado: (2021)

Overview of AFP Detector
por: Auriol, Adrien
Publicado: (2023)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Analysis of serum alpha-fetoprotein (AFP) and AFP-L3 levels by protein microarray
por: Wu, Min, et al.
Publicado: (2018)

A Logistic Regression Model for Noninvasive Prediction of AFP-Negative Hepatocellular Carcinoma
por: Luo, Chang-Liang, et al.
Publicado: (2019)

Status of the AFP Project in ATLAS
por: Tasevsky, Marek
Publicado: (2017)

ATLAS AFP: Status and Prospects
por: Newman, Paul
Publicado: (2018)

The AFP detector control system
por: Oleiro Seabra, Luis Filipe, et al.
Publicado: (2017)

The AFP and CT-PPS projects
por: Royon, C., et al.
Publicado: (2015)

Physics goals and status of AFP
por: Trzebinski, Maciej
Publicado: (2015)

Backgrounds in AFP Detector Estimation
por: Huang, Yicong
Publicado: (2016)

The tracking system of the AFP detector.
por: Dyndal, M
Publicado: (2014)

The AFP Detector Control System
por: Oleiro Seabra, Luis Filipe
Publicado: (2017)

Analysis with AFP and ATLAS Detectors
por: Erland, Paula Agnieszka
Publicado: (2022)

Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma
por: Gerry, Andrew B, et al.
Publicado: (2013)

The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma
por: Huang, Yu-Liang, et al.
Publicado: (2019)

Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma
por: Vongsuvanh, Roslyn, et al.
Publicado: (2016)

Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma
por: Lin, Zuyuan, et al.
Publicado: (2023)

Both the serum AFP test and AFP/GPC3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma
por: Wang, Bingzhi, et al.
Publicado: (2021)

Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases
por: Wang, Ting, et al.
Publicado: (2017)

AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis
por: Zhou, Jian-Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6702767ihvbs5dkqmj32ukbotq